​

Funding Round

Series C - Affinivax

Series C - Affinivax

Investment Firm

Overview

Affinivax is a biopharmaceutical company developing vaccines that target infectious diseases.

Announced Date

Jan 08, 2021

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

Foresite Capital

Foresite Capital

Foresite Capital is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

Rock Springs Capital

Rock Springs Capital

Rock Springs Capital is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

Participant Investors

11

Investor Name
Participant InvestorEcoR1 Capital
Participant InvestorForesite Capital
Participant InvestorT. Rowe Price
Participant InvestorWellington Management
Participant InvestorBlackRock

Round Details and Background

Affinivax raised $226000000 on 2021-01-08 in Series C

Affinivax is a biopharmaceutical company developing vaccines that target infectious diseases.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 08, 2021
Series C - Affinivax
13-226.0M
Mar 09, 2021
Grant - Affinivax
1-22.0M
Jan 05, 2018
Venture Round - Affinivax
-7.0M
Feb 05, 2016
Series A - Affinivax
1-2.5M

Recent Activity

There is no recent news or activity for this profile.